Kate Vandyke
Kate Vandyke
Post-doctoral Research Fellow, University of Adelaide
Verified email at adelaide.edu.au
TitleCited byYear
Dysregulation of bone remodeling by imatinib mesylate
K Vandyke, S Fitter, AL Dewar, TP Hughes, ACW Zannettino
Blood 115 (4), 766-774, 2010
1072010
The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo
K Vandyke, AL Dewar, P Diamond, S Fitter, CG Schultz, NA Sims, ...
Journal of Bone and Mineral Research 25 (8), 1759-1770, 2010
722010
Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis
K Vandyke, AL Dewar, AN Farrugia, S Fitter, LB To, TP Hughes, ...
Leukemia 23 (5), 994, 2009
512009
Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion
S Fitter, K Vandyke, S Gronthos, ACW Zannettino
Journal of molecular endocrinology 48 (3), 229-240, 2012
452012
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML …
S Fitter, K Vandyke, CG Schultz, D White, TP Hughes, ACW Zannettino
The Journal of Clinical Endocrinology & Metabolism 95 (8), 3763-3767, 2010
422010
SAMSN1 is a tumor suppressor gene in multiple myeloma
JE Noll, DR Hewett, SA Williams, K Vandyke, C Kok, LB To, ...
Neoplasia 16 (7), 572-585, 2014
412014
Imatinib mesylate causes growth plate closure in vivo
K Vandyke, AL Dewar, S Fitter, D Menicanin, LB To, TP Hughes, ...
Leukemia 23 (11), 2155, 2009
372009
EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair
A Arthur, RA Panagopoulos, L Cooper, D Menicanin, IH Parkinson, ...
Journal of Bone and Mineral Research 28 (4), 926-935, 2013
352013
Circulating N‐cadherin levels are a negative prognostic indicator in patients with multiple myeloma
K Vandyke, AWS Chow, SA Williams, LB To, ACW Zannettino
British journal of haematology 161 (4), 499-507, 2013
292013
The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma
ZY Gan, S Fitter, K Vandyke, LB To, ACW Zannettino, SK Martin
European journal of haematology 94 (4), 343-354, 2015
212015
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects
K Vandyke, S Fitter, J Drew, S Fukumoto, CG Schultz, NA Sims, DT Yeung, ...
The Journal of Clinical Endocrinology & Metabolism 98 (1), 67-76, 2013
172013
EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling
S Hemming, D Cakouros, J Codrington, K Vandyke, A Arthur, ...
The FASEB Journal 31 (3), 1011-1027, 2016
162016
The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
K Vandyke, S Fitter, ACW Zannettino
Blood cancer journal 1 (2), e2, 2011
152011
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma
JE Noll, K Vandyke, DR Hewett, KM Mrozik, RJ Bala, SA Williams, CH Kok, ...
Journal of hematology & oncology 8 (1), 106, 2015
142015
Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress
CT Wallington-Beddoe, MK Bennett, K Vandyke, L Davies, JR Zebol, ...
Oncotarget 8 (27), 43602, 2017
132017
Immunomodulatory properties of induced pluripotent stem cell‐derived mesenchymal cells
J Ng, K Hynes, G White, KN Sivanathan, K Vandyke, PM Bartold, ...
Journal of cellular biochemistry 117 (12), 2844-2853, 2016
132016
Engineering interaction between bone marrow derived endothelial cells and electrospun surfaces for artificial vascular graft applications
F Ahmed, NK Dutta, A Zannettino, K Vandyke, NR Choudhury
Biomacromolecules 15 (4), 1276-1287, 2014
132014
Identification of novel EZH2 targets regulating osteogenic differentiation in mesenchymal stem cells
S Hemming, D Cakouros, K Vandyke, MJ Davis, ACW Zannettino, ...
Stem cells and development 25 (12), 909-921, 2016
122016
Therapeutic targeting of N‐cadherin is an effective treatment for multiple myeloma
KM Mrozik, CM Cheong, D Hewett, AWS Chow, OW Blaschuk, ...
British journal of haematology 171 (3), 387-399, 2015
112015
Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo
CM Cheong, AWS Chow, S Fitter, DR Hewett, SK Martin, SA Williams, ...
Experimental cell research 332 (1), 24-38, 2015
102015
The system can't perform the operation now. Try again later.
Articles 1–20